Apnimed (APMD) CEO Kevin Lind Receives Derivative Awards

What Happened
Kevin Robert Lind, CEO of Apnimed, was the subject of multiple derivative transactions reported on a Form 4 filed 2026-08-03. The filing shows a series of grants (A) and corresponding dispositions to the issuer (D) involving a total of 1,478,238 derivative shares/options at a $0.00 price (non‑cash). Specific reported actions:

• Grants: 74,128; 1,186,278; 108,916 (8/03/2026) and 108,916 (7/30/2026) — total granted = 1,478,238 (all $0).
• Dispositions to issuer (likely reclassifications/exchanges of previously held instruments): 74,128; 1,186,278; 108,916 (all reported 8/03/2026).
  These are derivative awards/reclassifications reported as $0 transactions, not cash purchases or market sales.

Key Details

• Transaction dates and prices: Grants dated 2026-07-30 (108,916 @ $0) and 2026-08-03 (74,128; 1,186,278; 108,916 — all @ $0). Dispositions to issuer recorded 2026-08-03 (same amounts, $0).
• Total derivative instruments involved: 1,478,238 shares/options (aggregate). Reported dollar value: $0 (non‑cash).
• Shares owned after transaction: Not specified in the provided filing summary.
• Notable footnotes:
  • F1: A reclassification occurred — each Class A common share was reclassified into one share of common stock (Rule 16b‑7 / 16b‑3 exemption).
  • F2/F3: Vesting schedules apply to the options/awards: one award vests 25% after 12 months from Mar 6, 2025 with the remainder vesting quarterly over 36 months; another vests 25% after 12 months from June 1, 2026 with the remainder vesting monthly over 36 months, subject to continued service.
• Timeliness: Filing dated 2026-08-03 covers transactions on 2026-07-30 and 2026-08-03; the filing itself does not indicate a late-report flag in the summary provided.

Context

• These were derivative awards and reclassifications (non‑cash). That typically means options or stock awards were granted or converted, subject to the vesting schedules noted — not open‑market buying or selling.
• Because the transactions are $0 grants/reclassifications, they reflect compensation or structural changes (e.g., reclassification), not a market purchase or sale that signals immediate insider buying or selling.